CRISPR/Cas9-based gene therapy for Angelman syndrome

基于 CRISPR/Cas9 的 Angelman 综合征基因疗法

基本信息

  • 批准号:
    10490828
  • 负责人:
  • 金额:
    $ 54.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-15 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by deletion or mutation of the maternal allele of UBE3A. UBE3A is biallelically expressed in nearly all cells of the body except in mature neurons, where the paternal allele is silenced by an extremely long non-coding RNA called UBE3A-ATS. In light of this biology, the most direct way to treat behavioral dysfunctions associated with AS is to unsilence the intact paternal UBE3A allele. CRISPR/Cas9 technology can be used to target specific regions of the mammalian genome for mutagenesis or transcriptional repression. In unpublished studies, we generated hundreds of S. pyogenes (Sp)Cas9 guide RNAs (gRNAs) that target regions throughout UBE3A-ATS. Several of these gRNAs, when transfected along with SpCas9, potently unsilenced paternal Ube3a in cultured mouse cortical neurons. Some of our most effective gRNAs targeted a region of Ube3a-ATS that is conserved between mice and humans, making it possible to translate our findings to human neurons. Here, we will test the central hypothesis that CNS-directed delivery of Cas9 and a gRNA that targets Ube3a-ATS can enduringly unsilence paternal UBE3A and treat behavioral phenotypes associated with Angelman syndrome. We will use adeno-associated virus (AAV) for delivery because it can drive gene expression for years in the brain. Pilot studies with S. aureus (Sa)Cas9, a smaller Cas9 variant, suggest that our gene therapy approach can be used to unsilence paternal Ube3a in mice for at least three months. To advance this innovative gene therapy towards the clinic, we will evaluate efficacy, on- and off-target effects, and mechanism of action of candidate therapeutic SaCas9 gRNAs that target Ube3a-ATS. We will use cultured neurons from AS model mice and AS-derived human neurons. We will package SaCas9 and an optimized gRNA into a single AAV vector, and then evaluate unsilencing efficacy and longevity for up to two years in mice, as well as biodistribution and toxicity. Lastly, we will evaluate the extent to which AAV-mediated delivery of this CRISPR/Cas9-based gene therapy treats behavioral phenotypes in AS model mice.
项目摘要 Angelman综合征(AS)是一种严重的神经发育障碍, UBE 3A的母系等位基因。UBE 3A在除了成熟的细胞外的几乎所有细胞中都有双等位基因表达。 在神经元中,父本等位基因被称为UBE 3A-ATS的超长非编码RNA沉默。在 根据这种生物学,治疗与AS相关的行为功能障碍的最直接方法是打破沉默, 完整的父亲UBE 3A等位基因。CRISPR/Cas9技术可用于靶向组织的特定区域 用于诱变或转录抑制的哺乳动物基因组。在未发表的研究中, 几百个S。化脓性链球菌(Sp)Cas9引导RNA(gRNA),其靶向整个UBE 3A-ATS的区域。几 这些gRNA中,当与SpCas 9一起沿着转染时,在培养的小鼠中有效地使父本Ube 3a不沉默。 皮质神经元我们的一些最有效的gRNA靶向Ube 3a-ATS的保守区域, 在小鼠和人类之间的差异,使我们的发现转化为人类神经元成为可能。在这里,我们将测试 CNS指导的Cas9和靶向Ube 3a-ATS的gRNA的递送的中心假设可以 非沉默父亲UBE 3A和治疗与Angelman相关的行为表型 综合征我们将使用腺相关病毒(AAV)进行递送,因为它可以驱动基因表达, 岁月在脑中与S.金黄色葡萄球菌(Sa)Cas9,一种较小的Cas9变体,表明我们的基因 治疗方法可用于在小鼠中使父本Ube 3a不沉默至少三个月。推进这一 创新的基因治疗走向临床,我们将评估疗效,对和脱靶效应,和机制 靶向Ube 3a-ATS的候选治疗性SaCas 9 gRNA的作用。我们将使用培养的神经元 AS模型小鼠和AS衍生的人神经元。我们将把SaCas 9和优化的gRNA包装成一个 单个AAV载体,然后在小鼠中评估长达两年的非沉默功效和寿命,以及 生物分布和毒性。最后,我们将评估AAV介导的这种递送的程度。 基于CRISPR/Cas9的基因疗法治疗AS模型小鼠的行为表型

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mark J. Zylka其他文献

The environmental neuroactive chemicals list of prioritized substances for human biomonitoring and neurotoxicity testing: A database and high-throughput toxicokinetics approach
  • DOI:
    10.1016/j.envres.2024.120537
  • 发表时间:
    2025-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Julia E. Rager;Lauren E. Koval;Elise Hickman;Caroline Ring;Taylor Teitelbaum;Todd Cohen;Giulia Fragola;Mark J. Zylka;Lawrence S. Engel;Kun Lu;Stephanie M. Engel
  • 通讯作者:
    Stephanie M. Engel
Correction to: Chd8 haploinsufficiency impairs early brain development and protein homeostasis later in life
  • DOI:
    10.1186/s13229-021-00438-6
  • 发表时间:
    2021-05-08
  • 期刊:
  • 影响因子:
    5.500
  • 作者:
    Jessica A. Jiménez;Travis S. Ptacek;Alex H. Tuttle;Ralf S. Schmid;Sheryl S. Moy;Jeremy M. Simon;Mark J. Zylka
  • 通讯作者:
    Mark J. Zylka

Mark J. Zylka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mark J. Zylka', 18)}}的其他基金

Development of a deep neural network to measure spontaneous pain from mouse facial expressions
开发深度神经网络来测量小鼠面部表情的自发疼痛
  • 批准号:
    10094266
  • 财政年份:
    2020
  • 资助金额:
    $ 54.07万
  • 项目类别:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
开发深度神经网络来测量小鼠面部表情的自发疼痛
  • 批准号:
    10579988
  • 财政年份:
    2020
  • 资助金额:
    $ 54.07万
  • 项目类别:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
开发深度神经网络来测量小鼠面部表情的自发疼痛
  • 批准号:
    10717670
  • 财政年份:
    2020
  • 资助金额:
    $ 54.07万
  • 项目类别:
Development of a deep neural network to measure spontaneous pain from mouse facial expressions
开发深度神经网络来测量小鼠面部表情的自发疼痛
  • 批准号:
    10349447
  • 财政年份:
    2020
  • 资助金额:
    $ 54.07万
  • 项目类别:
Environmental-use chemicals that target pathways linked to autism and other neurodevelopmental disorders
针对与自闭症和其他神经发育障碍相关途径的环境使用化学品
  • 批准号:
    10402265
  • 财政年份:
    2019
  • 资助金额:
    $ 54.07万
  • 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
  • 批准号:
    10237150
  • 财政年份:
    2019
  • 资助金额:
    $ 54.07万
  • 项目类别:
Environmental-use chemicals that target pathways linked to autism and other neurodevelopmental disorders
针对与自闭症和其他神经发育障碍相关途径的环境使用化学品
  • 批准号:
    10618242
  • 财政年份:
    2019
  • 资助金额:
    $ 54.07万
  • 项目类别:
CRISPR/Cas9-based gene therapy for Angelman syndrome
基于 CRISPR/Cas9 的 Angelman 综合征基因疗法
  • 批准号:
    10011898
  • 财政年份:
    2019
  • 资助金额:
    $ 54.07万
  • 项目类别:
Identification of candidate environmental risks for autism
识别自闭症的候选环境风险
  • 批准号:
    9525549
  • 财政年份:
    2017
  • 资助金额:
    $ 54.07万
  • 项目类别:
Lipid kinase regulation of pain signaling and sensitization
脂质激酶对疼痛信号传导和敏化的调节
  • 批准号:
    9279273
  • 财政年份:
    2013
  • 资助金额:
    $ 54.07万
  • 项目类别:

相似海外基金

Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
  • 批准号:
    502556
  • 财政年份:
    2024
  • 资助金额:
    $ 54.07万
  • 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
  • 批准号:
    10659303
  • 财政年份:
    2023
  • 资助金额:
    $ 54.07万
  • 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
  • 批准号:
    10674405
  • 财政年份:
    2023
  • 资助金额:
    $ 54.07万
  • 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
  • 批准号:
    10758772
  • 财政年份:
    2023
  • 资助金额:
    $ 54.07万
  • 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
  • 批准号:
    10676499
  • 财政年份:
    2023
  • 资助金额:
    $ 54.07万
  • 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
  • 批准号:
    2748611
  • 财政年份:
    2022
  • 资助金额:
    $ 54.07万
  • 项目类别:
    Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
  • 批准号:
    10532032
  • 财政年份:
    2022
  • 资助金额:
    $ 54.07万
  • 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
  • 批准号:
    22K05630
  • 财政年份:
    2022
  • 资助金额:
    $ 54.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
  • 批准号:
    10525070
  • 财政年份:
    2022
  • 资助金额:
    $ 54.07万
  • 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
  • 批准号:
    10689017
  • 财政年份:
    2022
  • 资助金额:
    $ 54.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了